Human papillomavirus (HPV) testing is increasingly being incorporated into cervical cancer screening. The Validation of HPV Genotyping Tests (VALGENT) is a framework designed to evaluate the clinical performance of various HPV tests relative to that of the validated and accepted comparator test in a formalized and uniform manner. The aim of this study was to evaluate the clinical performance of the HPV-Risk assay with samples from the VALGENT-3 panel and to compare its performance to that of the clinically validated Hybrid Capture 2 assay (HC2). The VALGENT-3 panel comprises 1,300 consecutive samples from women participating in routine cervical cancer screening and is enriched with 300 samples from women with abnormal cytology. DNA was extr...
In this diagnostic test validation study, we assessed the clinical accuracy and HPV genotyping perfo...
Human papillomavirus (HPV) assays used in cervical cancer screening should be clinically validated a...
<p><b>BACKGROUND: </b>Cervical cancer screening programs are switching from cytolo...
Background: The VALidation of HPV GENoyping Tests (VALGENT) framework is designed for comparison and...
Only clinically validated human papillomavirus (HPV) tests should be used in cervical cancer screeni...
The Validation of Human Papillomavirus (HPV) Genotyping Tests (VALGENT) studies offer an opportunity...
In 2012, VALidation of human papillomavirus (HPV) GENotyping Tests (VALGENT) was initiated to provid...
<p>As the demand for human papillomavirus (HPV)-related cervical screening increases, emerging...
<p><b>BACKGROUND: </b>The benefit of HPV testing for cervical cancer screening and...
<p>The Validation of Human Papillomavirus (HPV) Genotyping Tests (VALGENT) studies offer an op...
<p>In this diagnostic test validation study, we assessed the clinical accuracy and HPV genotyp...
Background: Cervical cancer screening programs are switching from cytology-based screening to high-r...
<p><b>BACKGROUND: </b>Testing for high-risk HPV is more effective in primary cervi...
In this diagnostic test validation study, we assessed the clinical accuracy and HPV genotyping perfo...
Aim: The VALidation of HPV GENotyping Tests (VALGENT) is a framework for comparison and validation o...
In this diagnostic test validation study, we assessed the clinical accuracy and HPV genotyping perfo...
Human papillomavirus (HPV) assays used in cervical cancer screening should be clinically validated a...
<p><b>BACKGROUND: </b>Cervical cancer screening programs are switching from cytolo...
Background: The VALidation of HPV GENoyping Tests (VALGENT) framework is designed for comparison and...
Only clinically validated human papillomavirus (HPV) tests should be used in cervical cancer screeni...
The Validation of Human Papillomavirus (HPV) Genotyping Tests (VALGENT) studies offer an opportunity...
In 2012, VALidation of human papillomavirus (HPV) GENotyping Tests (VALGENT) was initiated to provid...
<p>As the demand for human papillomavirus (HPV)-related cervical screening increases, emerging...
<p><b>BACKGROUND: </b>The benefit of HPV testing for cervical cancer screening and...
<p>The Validation of Human Papillomavirus (HPV) Genotyping Tests (VALGENT) studies offer an op...
<p>In this diagnostic test validation study, we assessed the clinical accuracy and HPV genotyp...
Background: Cervical cancer screening programs are switching from cytology-based screening to high-r...
<p><b>BACKGROUND: </b>Testing for high-risk HPV is more effective in primary cervi...
In this diagnostic test validation study, we assessed the clinical accuracy and HPV genotyping perfo...
Aim: The VALidation of HPV GENotyping Tests (VALGENT) is a framework for comparison and validation o...
In this diagnostic test validation study, we assessed the clinical accuracy and HPV genotyping perfo...
Human papillomavirus (HPV) assays used in cervical cancer screening should be clinically validated a...
<p><b>BACKGROUND: </b>Cervical cancer screening programs are switching from cytolo...